These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25857559)

  • 1. Mycobacterium Tuberculosis Biofilm - A new perspective.
    Nayak N
    Indian J Tuberc; 2015 Jan; 62(1):4-6. PubMed ID: 25857559
    [No Abstract]   [Full Text] [Related]  

  • 2. Keto-mycolic acid-dependent pellicle formation confers tolerance to drug-sensitive Mycobacterium tuberculosis.
    Sambandan D; Dao DN; Weinrick BC; Vilchèze C; Gurcha SS; Ojha A; Kremer L; Besra GS; Hatfull GF; Jacobs WR
    mBio; 2013 May; 4(3):e00222-13. PubMed ID: 23653446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria.
    Ojha AK; Baughn AD; Sambandan D; Hsu T; Trivelli X; Guerardel Y; Alahari A; Kremer L; Jacobs WR; Hatfull GF
    Mol Microbiol; 2008 Jul; 69(1):164-74. PubMed ID: 18466296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changes in mycolic acid structures caused by hadC mutation have a dramatic effect on the virulence of Mycobacterium tuberculosis.
    Slama N; Jamet S; Frigui W; Pawlik A; Bottai D; Laval F; Constant P; Lemassu A; Cam K; Daffé M; Brosch R; Eynard N; Quémard A
    Mol Microbiol; 2016 Feb; 99(4):794-807. PubMed ID: 26538472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IQG-607 abrogates the synthesis of mycolic acids and displays intracellular activity against Mycobacterium tuberculosis in infected macrophages.
    Rodrigues-Junior VS; dos Santos Junior AA; Villela AD; Belardinelli JM; Morbidoni HR; Basso LA; Campos MM; Santos DS
    Int J Antimicrob Agents; 2014 Jan; 43(1):82-5. PubMed ID: 24139881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exocarpic acid inhibits mycolic acid biosynthesis in Mycobacterium tuberculosis.
    Koch M; Bugni TS; Sondossi M; Ireland CM; Barrows LR
    Planta Med; 2010 Oct; 76(15):1678-82. PubMed ID: 20506078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biosynthesis and regulation of mycolic acids in Mycobacterium tuberculosis--a review].
    Luo H; Pang L; Xie J
    Wei Sheng Wu Xue Bao; 2012 Feb; 52(2):146-51. PubMed ID: 22586991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological aspects of mycolic acids: an important target against Mycobacterium tuberculosis.
    de Souza MV; Ferreira Mde L; Pinheiro AC; Saraiva MF; de Almeida MV; Valle MS
    ScientificWorldJournal; 2008 Jul; 8():720-51. PubMed ID: 18677428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoniazid activity is terminated by bacterial persistence.
    Mitchison DA; Jindani A; Davies GR; Sirgel F
    J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
    [No Abstract]   [Full Text] [Related]  

  • 10. Persistence, not resistance, is the cause of loss of isoniazid effect.
    Wallis RS; Palaci M; Eisenach K
    J Infect Dis; 2007 Jun; 195(12):1870-1; author reply 1872-3. PubMed ID: 17492604
    [No Abstract]   [Full Text] [Related]  

  • 11. Structure, function and biogenesis of the mycobacterial cell wall.
    Brennan PJ; Besra GS
    Biochem Soc Trans; 1997 Feb; 25(1):188-94. PubMed ID: 9056869
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis.
    Sacchettini JC; Rubin EJ; Freundlich JS
    Nat Rev Microbiol; 2008 Jan; 6(1):41-52. PubMed ID: 18079742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds
    Li W; Sanchez-Hidalgo A; Jones V; de Moura VC; North EJ; Jackson M
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycolic acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in Mycobacterium tuberculosis.
    Alahari A; Alibaud L; Trivelli X; Gupta R; Lamichhane G; Reynolds RC; Bishai WR; Guerardel Y; Kremer L
    Mol Microbiol; 2009 Mar; 71(5):1263-77. PubMed ID: 19183278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of isoniazid killing: clarity through the scope of genetics.
    Vilchèze C; Jacobs WR
    Annu Rev Microbiol; 2007; 61():35-50. PubMed ID: 18035606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions.
    Basaraba RJ; Ojha AK
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28597824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Primary resistance of Mycobacterium tuberculosis].
    Barranquero Arola M; Gorritxo Gil B; Goiriena de Gandarias J
    Rev Sanid Hig Publica (Madr); 1984; 58(11-12):1107-15. PubMed ID: 6443589
    [No Abstract]   [Full Text] [Related]  

  • 18. Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro.
    Zhang S; Shi W; Feng J; Zhang W; Zhang Y
    Emerg Microbes Infect; 2017 Apr; 6(4):e28. PubMed ID: 28442751
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycolic acids: structures, biosynthesis, and beyond.
    Marrakchi H; Lanéelle MA; Daffé M
    Chem Biol; 2014 Jan; 21(1):67-85. PubMed ID: 24374164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial drugs: hitting the tuberculosis wall.
    Harrison C
    Nat Rev Drug Discov; 2013 Aug; 12(8):578-9. PubMed ID: 23903215
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.